Duloxetine Capsule, Delayed Release
Product Images NDC 51655-237

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 51655-237). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 237 25 Master Bottle Label Approval Rev A 04 21)

This is a medication called Duloxetine which is encapsulated as delayed-release capsules. The pack contains 60 capsules with each capsule containing enteric-coated pellets of 67.3mg Duloxetine Hydrochloride equivalent to 60mg Duloxetine. The medication should be kept at temperatures ranging from 15°C to 30°C and stored in its original container. The medication is repackaged by Northwind Pharmaceuticals and contains the NDC number 51655-237-25, and it is available only with a prescription. The pack information contains the Lot number, Expiration Date, and Serial number of the medication, which are all important details for the pharmacist.*

FDA Label Image

Figure1 (Duloxetine Fig1)

FDA Label Image

Figure10 (Duloxetine Fig10)

This is a description of a medication called Duloxetine, prescribed once daily in doses of either 60 or 120mg. The text features a graph or chart displaying pain improvement, measured as percent improvement from baseline. There is mention of a term 'Placebo' but it is not clear how it is related to the medication being described.*

FDA Label Image

Figure2 (Duloxetine Fig2)

The graph represents the proportion of patients who have a relapse over time after being randomized to either placebo or duloxetine treatment. The x-axis represents the time from randomization to relapse in days, and the y-axis represents the proportion of patients who experience a relapse as a percentage. The graph shows that patients who were treated with duloxetine had a lower proportion of relapses compared to those who received the placebo treatment.*

FDA Label Image

Figure3 (Duloxetine Fig3)

The text presents a table entitled "Percentage of Patients Improved" with four rows of treatments: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and Placebo. The table also includes a row titled "Percent Improvement in Pain from Baseline." However, due to the presence of non-English characters and the lack of context, it is not possible to provide a more detailed description.*

FDA Label Image

Figure4 (Duloxetine Fig4)

FDA Label Image

Figure5 (Duloxetine Fig5)

The text seems to be a chart or graph displaying data about the percentage of patients who improved and the percentage of pain improvement after taking Duloxetine in different doses. However, it is not possible to provide a useful description without more context and information.*

FDA Label Image

Figure6 (Duloxetine Fig6)

FDA Label Image

Figure8 (Duloxetine Fig8)

This is a description of a medical treatment involving Duloxetine, a medication used to treat depression, anxiety, and chronic pain disorders. The recommended dose is either 60 or 120 mg once a day. The text also includes a graph or chart indicating the percentage of improvement in pain from baseline, but the image is not available through the text.*

FDA Label Image

Figure9 (Duloxetine Fig9)

This is a chart comparing the effectiveness of Placebo and Duloxetine 60 mg once daily in reducing pain. The chart shows the percentage improvement in pain from baseline for different time intervals (ranging from 10 to 100). There are some illegible characters and numbers.*

FDA Label Image

Structure (Duloxetine Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.